Memorandum on Presidential Decision on Major Drug Transit Countries or Major Illicit Drug Producing Countries for Fiscal Year 2023

September 15, 2022

Presidential determination
No. 2022-23

MEMORANDUM FOR THE SECRETARY OF STATE

SUBJECT: Presidential decision on major drug transit
or major illicit drug producing countries for
Financial year 2023

By the authority vested in me as President by the Constitution and laws of the United States, including Section 706(1) of the Foreign Relations Authorization Act, Fiscal Year 2003 (Public Law 107 -228) (FRAA), I hereby identify the following countries as major drug transit countries or major illicit drug producing countries: Afghanistan, Bahamas, Belize, Bolivia, Burma, Colombia, Costa Rica, Dominican Republic, Ecuador , El Salvador, Guatemala, Haiti, Honduras, India, Jamaica, Laos, Mexico, Nicaragua, Pakistan, Panama, Peru and Venezuela.

A country’s presence on the above list does not reflect its government’s drug enforcement efforts or its level of cooperation with the United States. In accordance with the statutory definition of a major drug transit country or a major illicit drug producing country set out in sections 481(e)(2) and 481(e)(5) of the Foreign Assistance Act of 1961, as amended (Public Law 87-195) (FAA), the reason countries are placed on the list is the combination of geographic, trade, and economic factors that permit the transit or production of drugs, even if a government committed to strong and diligent narcotics control and law enforcement measures.

Pursuant to FRAA Section 706(2)(A), I hereby designate Afghanistan, Bolivia, Burma and Venezuela as manifestly not having made substantial efforts in the past 12 months to comply with their obligations under international counter-narcotics agreements and to take action as required by Section 489(a)(1) of the FAA. This determination includes justifications for the designations of Afghanistan, Bolivia, Burma and Venezuela, as required by FRAA Section 706(2)(B). I have also determined, pursuant to the provisions of FRAA Section 706(3)(A), that U.S. programs supporting Afghanistan, Bolivia, Burma, and Venezuela are vital to the national interests of the States -United.

Coping with the continuing and increasingly staggering toll of the drug abuse and overdose epidemic in the United States, which tragically claimed the lives of nearly 108,000 people in 2021, remains a top public health priority. of my administration. As part of our 2022 national drug strategy, my administration will focus on key drivers of the epidemic, including untreated drug addiction and drug trafficking, and will redouble efforts to strengthen foreign partnerships to to combat drug production and trafficking, in particular to address the common challenge of synthetic drugs. .

My administration’s budget request for fiscal year 2023 requests $24.3 billion to support evidence-based prevention and treatment, including harm reduction and recovery support services, with targeted investments to meet the needs of populations most at risk for overdose and substance use disorders. The budget request also includes significant investments to reduce the supply of illicit drugs from beyond our borders.

The United States is committed to working with countries in the Western Hemisphere as neighbors and partners to address our common drug production, trafficking, and use challenges, and to counter the deleterious impact of related corruption. to narcotics. My Administration is expanding global cooperation to strengthen efforts to combat the production and trafficking of dangerous synthetic drugs that are responsible for so many of our overdose deaths, particularly fentanyl, its analogues and methamphetamine. We will seek to expand cooperation with China, India and other chemical source countries to disrupt the global flow of synthetic drugs and their chemical precursors. As part of the United States-Mexico Bicentennial Framework for Security, Public Health, and Community Safety, we support and encourage Mexican efforts to target clandestine drug labs, chemists, and companies involved in diversion. chemicals; adopt stronger chemical control and accountability frameworks; increase the prohibition of chemical precursors and finished synthetic drugs in transit; and to arrest key organized crime figures involved in the synthesis and trafficking of fentanyl and methamphetamine and in the laundering of drug proceeds. The United States is encouraged by Afghanistan’s ban on the cultivation, production and trafficking of the opium poppy and will monitor the implementation of this ban. The United States is also encouraged by Bolivia’s counternarcotics efforts over the past year, including increased cooperation with international partners. I encourage the Bolivian government to take further steps to protect the country’s legal coca markets from criminal exploitation, to reduce illicit coca cultivation which continues to exceed legal limits under Bolivian national laws for the use medicinal and traditional, and to pursue international collaboration to disrupt drug traffickers. Additionally, while the above list is centered on the drug trafficking law and the production of herbal drugs and synthetic opioids that significantly affect the United States, the fight against the global proliferation of other dangerous synthetic drugs remains a key drug control priority for my Administration. .

You are authorized and instructed to submit this designation, together with the justification memoranda of Afghanistan, Bolivia, Burma, and Venezuela, under section 706 of the FRAA, to Congress, and to publish this decision. in the Federal Register.

JOSEPH R. BIDEN JR.

JOSEPH R. BIDEN JR.

About Rhonda Lee

Check Also

Mass. Nursing facilities operator settles with DOJ over substance abuse discrimination claims

Next Step Healthcare, an operator of 21 skilled nursing facilities in Massachusetts, has settled with …